Buy Afanix 40 MG (Afatinib) - Mediaid pharmacy Bangladesh

Afanix 40 MG (Afatinib)

Afatinib is basically Anti-Cancer Medicine and it is used for the first-line treatment of patients with metastatic non-small cell lung cancer.

Product Name : Afanix (Afatinib)
Generic Name : Afatinib Dimaleate INN
Formulation : Tablet
Available Pack Size : 30’s (3×10’s)
Available Strengths : 40 mg
Registrations : Bangladesh

Message Us on WhatsApp

Product Information

Afanix (Afatinib) 40mg is a selective and irreversible ErbB family blocker, targeting EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), used for the first-line treatment of patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumours carry non-resistant EGFR mutations. It works by covalently and irreversibly binding to the kinase domains of the ErbB receptor family, blocking the signalling cascade that drives tumour growth and survival. Manufactured by Beacon Pharmaceuticals PLC, Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.

Basic Product Information of Afanix (Afatinib) 40mg

Brand Name	Afanix (Afatinib)
Generic Name	Afatinib Dimaleate INN
Drug Class	Irreversible ErbB Family Blocker (EGFR/HER2/HER4 Tyrosine Kinase Inhibitor)
Available Strength	40mg
Formulation	Film-Coated Tablet
Pack Size	30 Tablets (3 Strips of 10 Tablets)
Primary Indication	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) with Non-Resistant EGFR Mutations
Regulatory Approvals	USFDA Approved (First-Line NSCLC and Second-Line Squamous NSCLC). EMA Approved.
Originator Brand	Gilotrif / Giotrif by Boehringer Ingelheim
Manufacturer	Beacon Pharmaceuticals PLC, Mymensingh, Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration	Registered in Bangladesh
Storage Conditions	Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children.

How Afanix (Afatinib) Works

Afanix contains Afatinib, a second-generation, selective and irreversible inhibitor of the ErbB receptor family, which includes EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). In certain non-small cell lung cancers, activating mutations in the EGFR gene, most commonly exon 19 deletions and the exon 21 L858R substitution, cause continuous, unregulated receptor signalling that drives tumour cell growth.

Unlike first-generation, reversible EGFR inhibitors, Afatinib covalently and irreversibly binds to the kinase domains of EGFR, HER2, and HER4, permanently blocking tyrosine kinase autophosphorylation. This down-regulates ErbB signalling across all targeted receptors simultaneously, giving Afanix broader and more sustained pathway inhibition than reversible first-generation TKIs, including activity against certain EGFR mutations that confer resistance to earlier agents.

Because of this targeted mechanism, Afanix is classified as a targeted therapy rather than conventional chemotherapy. It is taken as a once-daily oral tablet, allowing eligible patients to manage advanced NSCLC on an outpatient basis.

Indications for Afanix (Afatinib)

Afanix (Afatinib) is indicated for the following conditions:

First-Line Metastatic NSCLC

For the first-line treatment of adult patients with metastatic NSCLC whose tumours have non-resistant EGFR mutations, most commonly exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an approved test.

Second-Line Squamous NSCLC

For the treatment of adult patients with metastatic squamous NSCLC whose disease has progressed after platinum-based chemotherapy.

Benefits of Afanix (Afatinib) 40mg

Broader ErbB-Family Inhibition

By irreversibly blocking EGFR, HER2, and HER4 together, Afanix offers broader and more sustained pathway inhibition than first-generation, reversible EGFR inhibitors.

Proven First-Line Efficacy

Afatinib has demonstrated prolonged progression-free survival compared to standard platinum-based chemotherapy in EGFR mutation-positive metastatic NSCLC, with better control of cancer-related cough and breathlessness.

Convenient Once-Daily Dosing

Afanix is taken as a single oral tablet once daily, offering a simple, convenient regimen compared to intravenous chemotherapy schedules.

Affordable Alternative to Gilotrif

Afanix contains the same active ingredient as Gilotrif (Giotrif) by Boehringer Ingelheim, at a significantly lower cost, making long-term targeted lung cancer therapy more financially accessible.

No CYP450 Drug Interactions

Afatinib is not metabolised through the cytochrome P450 enzyme system, reducing the potential for certain drug-drug interactions common with other oral cancer therapies.

WHO-GMP and cGMP Certified

Produced by Beacon Pharmaceuticals PLC under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards, ensuring every batch of Afanix meets consistent quality, safety, and efficacy requirements.

How to Take Afanix (Afatinib)

Route: Oral, taken by mouth. Tablets should be swallowed whole and not chewed, crushed, dissolved, or divided.

Standard dose: 40mg once daily, taken at approximately the same time each day, until disease progression or unacceptable toxicity, exactly as directed by the prescribing oncologist.

With food: Take on an empty stomach, at least 1 hour before or 2 hours after a meal, as food significantly reduces absorption.

Missed dose: If a dose is missed, and the next scheduled dose is more than 8 hours away, take the missed dose as soon as remembered; otherwise, skip it and resume the normal schedule. Do not double up doses.

Dose reduction for toxicity: If dose reduction is required to manage adverse reactions such as severe diarrhoea, rash, or other toxicity, treatment is typically interrupted until the reaction resolves or improves, then resumed at a reduced dose (commonly in 10mg steps) as directed by the prescribing physician.

Renal impairment: No dose adjustment is required in mild to moderate renal impairment. In severe renal impairment, a reduced starting dose is generally recommended, and treatment should be closely supervised.

Hepatic impairment: No dose adjustment is required in mild or moderate hepatic impairment. Afanix has not been studied in severe hepatic impairment; use with caution and close monitoring if prescribed.

P-glycoprotein (P-gp) interactions: If a P-gp inhibitor is required and not tolerated, the daily dose may be reduced; if a P-gp inducer is required chronically, the daily dose may be increased as tolerated, under physician guidance.

Paediatric use: The safety and efficacy of Afanix in children and adolescents have not been established. No data are currently available.

Prescription Medication. Treatment with Afanix should not be initiated without confirmed EGFR mutation status from an approved test. Afanix has been associated with severe diarrhoea, serious skin reactions (including life-threatening bullous or exfoliative lesions), interstitial lung disease, and rare cases of significant liver injury. Treatment must be permanently discontinued if severe skin reactions or interstitial lung disease are confirmed. Always follow your prescribing oncologist’s instructions.

Monitoring and Dosage Adjustments

Regular monitoring is essential during Afanix treatment. Your healthcare provider will monitor for severe or persistent diarrhoea, which may require prompt antidiarrhoeal treatment, fluid replacement, and dose interruption. Monitoring also includes skin and mucosal reactions such as rash, dry skin, or mouth sores, signs of interstitial lung disease (new or worsening breathlessness, cough, or fever), liver function tests, renal function, and, in patients with cardiac risk factors, periodic assessment of left ventricular function. Report any severe diarrhoea, blistering skin reactions, breathlessness, or eye irritation to your doctor immediately.

Drug Interactions and Important Information

Afatinib is a substrate and inhibitor of the P-glycoprotein (P-gp) transporter. Coadministration with strong P-gp inhibitors (such as ketoconazole, verapamil, and ritonavir) may increase Afatinib exposure, while strong P-gp inducers (such as rifampicin, carbamazepine, and phenytoin) may reduce its effectiveness; dose adjustment may be required under physician guidance. Unlike many other targeted cancer therapies, Afatinib is not significantly metabolised by cytochrome P450 enzymes.

Use with caution in patients with a history of keratitis, dry eyes, or contact lens use, and inform your physician of any cardiac risk factors before starting treatment. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Afanix.

Side Effects and Precautions

Common Side Effects

Diarrhoea

Rash, acne, and dry skin

Stomatitis (mouth sores) and paronychia (nail inflammation)

Nausea and vomiting

Decreased appetite and weight loss

Epistaxis (nosebleeds)

Fatigue

Dry mouth and itching

Serious Warnings and Precautions

Severe or persistent diarrhoea, which may lead to dehydration and renal impairment if untreated.

Severe bullous, blistering, or exfoliative skin lesions, including rare Stevens-Johnson syndrome and toxic epidermal necrolysis.

Interstitial lung disease, including fatal cases. Withhold and evaluate promptly if suspected.

Hepatotoxicity, including rare cases of clinically apparent liver injury.

Keratitis and other ocular disturbances.

Left ventricular dysfunction in patients with cardiac risk factors.

Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding.

Who Should Use Afanix (Afatinib)?

Afanix is suitable for adult patients diagnosed with metastatic Non-Small Cell Lung Cancer whose tumours carry non-resistant EGFR mutations, most commonly exon 19 deletions or exon 21 L858R substitutions, confirmed by an approved EGFR mutation test, as a first-line treatment. It is also used as a second-line treatment for metastatic squamous NSCLC that has progressed after platinum-based chemotherapy. Afanix is prescribed by medical oncologists and thoracic oncology specialists experienced in biomarker-guided cancer therapy. A thorough medical assessment including EGFR mutation testing, baseline renal and liver function, and cardiac risk evaluation is required before initiating treatment.

Manufacturer: Beacon Pharmaceuticals PLC

Beacon Pharmaceuticals PLC is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards. Afanix is one of Beacon’s globally recognised specialty oncology products, offering an affordable and bioequivalent alternative to Gilotrif (Giotrif) by Boehringer Ingelheim at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Afanix (Afatinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Afanix (Afatinib) from Mediaid Pharmacy?

Afanix represents an important, targeted option in the first-line treatment of EGFR mutation-positive lung cancer. As the generic equivalent of Gilotrif (Giotrif) by Boehringer Ingelheim, it delivers the same active ingredient, Afatinib, with the same proven irreversible ErbB-family inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals PLC under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Afanix gives patients worldwide access to high-quality targeted lung cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Afatinib option with worldwide delivery, Afanix from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Afanix (Afatinib)

What is Afanix (Afatinib) used for?

Afanix (Afatinib) is used as first-line treatment for adult patients with metastatic Non-Small Cell Lung Cancer whose tumours carry non-resistant EGFR mutations, most commonly exon 19 deletions or exon 21 L858R substitutions. It is also used as a second-line treatment for metastatic squamous NSCLC that has progressed after platinum-based chemotherapy.

How should I take Afanix (Afatinib)?

Afanix is taken orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, as food reduces absorption. The standard dose is 40mg once daily. Dose reduction may be required to manage side effects such as severe diarrhoea or skin reactions. Always follow your oncologist’s exact instructions.

What strength is Afanix (Afatinib) available in?

Afanix is available in a 40mg film-coated tablet, supplied in a pack of 30 tablets (3 strips of 10). The 40mg strength is the standard recommended starting dose for most adult patients.

Is Afanix the same as Gilotrif (Afatinib by Boehringer Ingelheim)?

Yes. Afanix is the generic equivalent of Gilotrif (marketed as Giotrif in some regions). Both contain the same active ingredient, Afatinib, in the same dosage form and strength. Afanix is manufactured by Beacon Pharmaceuticals PLC in Bangladesh and delivers the same clinical mechanism as Gilotrif at a significantly lower cost.

What are the side effects of Afanix (Afatinib)?

Common side effects include diarrhoea, rash, dry skin, mouth sores, nail inflammation, nausea, and decreased appetite. Serious but less common risks include severe diarrhoea, severe skin reactions, interstitial lung disease, and liver injury. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.

Can Afanix be used with other medications?

Afatinib is not significantly metabolised by cytochrome P450 enzymes, but it is a substrate and inhibitor of the P-glycoprotein transporter, so strong P-gp inhibitors or inducers may require a dose adjustment. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Afanix.

Is Afanix (Afatinib) safe during pregnancy or breastfeeding?

No. Afanix is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.

Can I order Afanix (Afatinib) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Afanix (Afatinib) 40mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.

Order Afanix (Afatinib) 40mg with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp